Stock comparison
Genmab A/S
Jazz Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
JAZZ
Jazz Pharmaceuticals
Market cap
$15.05B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | JAZZ | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 46D | GMAB |
| Benjamin Graham | 64C | 58D | GMAB |
| Philip Fisher | 48D | 42D | GMAB |
| Peter Lynch | 25F | 36D | JAZZ |
| Joel Greenblatt | 76B | 44D | GMAB |
| Charlie Munger | 68C | 42D | GMAB |
| Terry Smith | 71C | 35D | GMAB |
Side-by-side metrics
| Metric | GMAB | JAZZ |
|---|---|---|
| Market cap | $16.5B | $15.05B |
| P/E (TTM) | 6.2x | 501.8x |
| EV/EBIT | 12.0x | 82.8x |
| ROIC (TTM) | 43.78% | -0.62% |
| Gross margin | 93.88% | 84.12% |
| Net margin | 18.23% | 0.66% |
| Revenue CAGR 5y | -18.45% | 8.37% |
| EPS CAGR 5y | -23.48% | - |
| Debt / Equity | 0.1x | 1.2x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- ROIC (TTM)43.78%vs -0.62%+101%
- P/E (TTM)6.2xvs 501.8x+99%
- Net margin18.23%vs 0.66%+96%
- Debt / Equity0.1xvs 1.2x+94%
JAZZ leads on
- Revenue CAGR 5y8.37%vs -18.45%+145%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.